Photo image of close-up of an individual's legs laying in wildflower field with an engineered mechanical yellow and magenta butterfly perched on a knee

A dramatic change through unprecedented response rates in heavily pre-treated patients1

Not an actual patient.

Rapid, durable responses were seen in the pivotal, phase 2 clinical trial with just a single infusion of TECELRA (n=44)1

43% ORR

(95% CI: 28, 59)

demonstrated in a heavily pre-treated, unresectable, and metastatic population

Partial response rate

39%

Complete response rate

5%

6months mDoR
(95% CI: 5, NR)

Patients with DoR ≥6 months

46%

Patients with DoR ≥12 months

39%

4.9weeks mTTR
(95% CI: 4.4, 8 weeks)

Individual best overall response after a single infusion of TECELRA in the phase 2 clinical trial2

Slide to view chart
Waterfall chart describing best overall response rate by percent change in baseline. Measures progressive disease, stable disease, and partial response
  • One patient in the clinical trial did not have a measurable target lesion per RECIST v1.1, and is not included in the above figure2

LIMITATION: These data do not determine the status of nontarget lesions or new lesions and cannot be used to distinguish stable disease, progressive disease, or response. Note that not every bar on the waterfall plot below the horizontal zero line represents a confirmed objective response. Target lesion shrinkage is not indicative of response; no efficacy conclusions can be drawn from these data.

TECELRA is the change you've been waiting for in the treatment of advanced SyS1,3,§
DoR=duration of response; HLA=human leukocyte antigen; MAGE=melanoma-associated antigen; mDoR=median duration of response; mTTR=median time to response; NR=not reached; ORR=overall response rate; RECIST=Response Evaluation Criteria In Solid Tumors; SyS=synovial sarcoma.
ORR was defined as partial response or better based on RECIST v1.1. Evaluated by independent review.1
In the clinical trial, patients had a median of 3 prior lines of systemic therapy (range: 1 to 12 lines). Prior therapies included ifosfamide (100%), doxorubicin (95%), pazopanib (48%), trabectedin (25%), dacarbazine (11%), and gemcitabine (11%).1
§ Adult patients who have received prior chemotherapy, are HLA-A*02 positive, and whose tumor expresses the MAGE‑A4 antigen.1